Pharma & Biotech Global Week in Review 1 Feb 2012 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

WHO, Gates, industry and NGO leaders elevate attention to neglected diseases (IP Watch) (Spicy IP)

European Commission orders Italy to drop patent linkage delaying generics (IP Watch)

EU: Taking unfair advantage: VIAGUARA successfully opposed: Case T-332/10 (IPKat) (Class 46)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Should the duration of pharmaceutical patents be extended? The WSJ debate (IPKat) (The SPC Blog)

The real reason why Salk refused to patent the polio vaccine (BIOtechNOW)

WHO, Gates, industry and NGO leaders elevate attention to neglected diseases (IP Watch) (Spicy IP)

Loss of patent protection on blockbuster drugs impact earnings of Pfizer and Eli Lilly (IP Solutions Blog)

Director Kazatchkine resigns from The Global Fund (IP Watch)

WHO Board plan for fake medicines mechanism excludes trade and IP (IP Watch)

Australia: Dr Gray/Royal Children’s Hospital dispute moves up to the Federal Court (Patentology)

Bulgaria: Supreme Administrative Court orders Bulgarian Patent Office to make publication of court judgment invalidating previous BPO decision concerning termination of AstraZeneca patent:  BPO v AstraZeneca (Kluwer Patent Blog)

EU: What’s the use of contraception? Don’t ask the EPO … – EPO BoA on use claims: T 1635/09 (IPKat)

Italy: European Commission orders Italy to drop patent linkage delaying generics (IP Watch)

US: Feds say senior Google execs knew about illicit pharma ads (Ars Technica)

US: CAFC remands part of Roche/Nova case; Roche wins remainder of appeal issues (IPBiz)

US: Of biomedical research, academic publishing and copyright – Research Works Act (HR 3699) (The 1709 Blog)

US: Design mark refused registration for various pharmaceucical preparations and pharmaceutical research services due to likelihood of confusion: In re Alvogen IP Co. Sarl (TTABlog)

US: False patent marking is constitutional: Simonian v. Allergan (Chicago IP Litigation Blog)

US: CAFC issues Streck II decision (Patent Docs)

US: Cancer institute sues biotech company for more than $1 billion charging IP theft (Patent Barista)

US: CDRH Issues its Strategic Priorities for 2012 (FDA Law Blog)

 

Products

Alimta (Pemetrexed) – US: Eli Lilly files patent infringement complaint against Accord Healthcare in response to Para IV certification filing (Patent Docs)

Astepro (Azelastine) – US: Meda Pharmaceuticals files patent infringement suit against Apotex and Perrigo in reponse to Para IV challenge (Patent Docs)

Fentora (Fentanyl citrate buccal) – US: Cephalon files patent infringement complaints against Mylan and Sandoz over ANDA filing (Patent Docs)

Fusilev (Levoleucovorin) – US: Spectrum Pharmaceuticals files patent infringement suit against Sandoz in response to Para IV challenge (Patent Docs)

Leflunomid and Teriflunomid – Germany: When the ravages of time contribute to patent infringement (PatLit)

Niaspan (Niacin) – US: Abbott files patent infringement sut against Cadila in reponse to Para IV certification (Patent Docs)

Nuedexta (Dextromethorphan hydrobromide and Quinidine sulphate) – PTO challenged after denying a patent term extension based on first commercial marketing or use grounds (FDA Law Blog)

NuvaRing – US: ALJ Pender grants motion to terminate investigation in Certain Vaginal Ring Birth Control Devices (337-TA-768) (ITC 337 Law Blog)

Panitumumab – Switzerland: Federal Administrative Court: SPC to be granted only if product falls within scope of protection of basic patent (Kluwer Patent Blog)

Thalidomide – Australia: Evergreening by business method? Patent Office says ‘No’!: Celgene Corporation (Patentology)

Valsartan – France: Court of First Instance orders ex parte preliminary injunctions against Sanofi: Novartis v Sanofi (EPLAW)

Viagra (Sildenafil) – EU: Taking unfair advantage: VIAGUARA successfully opposed: Case T-332/10 (IPKat) (Class 46)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 20,528 other followers

%d bloggers like this: